The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

versus first-line treatment with Keytruda (pembrolizumab) plus chemotherapy. Findings, demonstrated by the phase 2 PERLA ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating ... from the most ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

LOUISVILLE, Ky. -- Large tumor size and high disease grade were associated with an increased risk of early cancer-related ...

Natalie Willacy has so far poured $40,000 of her super into self-funding her own immunotherapy treatment with the groundbreaking drug Keytruda. Picture: Steve Pohlner It can be revealed Mr Butler ...